Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for
platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent
efficacy trials.